David Lieberman, M.D., weighs in on a new FDA-approved blood-based screening test for colorectal cancer. He says the blood-based test is “better than no screening,” but cautions that it is “inferior to other screening tests and should not replace one of the established screening tests.”

A financial earnings press release from ORYZON mentions that OHSU has opened an investigator-initiated study to evaluate the combination of iadademstat with venetoclax and azacitidine in patients with acute myeloid leukemia (AML).

Article focuses on OHSU-led research that reveals a promising approach to developing a universal influenza vaccine, a platform that also could be useful against the next pandemic. Jonah Sacha, M.D., says, “For viruses of pandemic potential, it’s critical to have something like this. We set out to test influenza, but we don’t know what’s going to come next.”

In an article about the longstanding trend of Washington patients coming to Oregon for abortion care, Alyssa Colwill, M.D., says OHSU has always been a "hub for SW Washington patients," and that Washingtonians represent the largest share of out-of-state abortion patients treated at OHSU.

A recent report led by U.S. Sen. Maria Cantwell, D-Wash., reveals the impact of the U.S. Supreme Court’s decision in 2022 to overturn a half-century of legal access to abortion nationwide. Even though Oregon has maintained abortion access, Maria Rodriguez, M.D., says, “We are getting a lot of patients from Idaho, and even more from states like California and Washington, where there are no bans, but people are struggling to get in to be seen in a timely fashion. People are far more likely to be in the second or third trimester due to delays, and a lot sicker.”

The OHSU Knight Cancer Institute supports the annual Susan G. Komen “More Than Pink” walk in Portland that aims to bring together survivors, supporters and advocates to advance Komen’s mission and provide support for people facing breast cancer.

Ophthalmology Breaking News reports on an OHSU study that identified a connection between specific proteins found in patients' tears and persistent pain experienced months after eye surgery.

The use of artificial intelligence applications like ChatGPT to document clinical visits. However, the story cites a study from OHSU noting that the software had an average of 23.6 errors per clinical case and that ChatGPT was not ready for use in a real-world ER setting.

Autobahn Therapeutics, an OHSU startup, has raised $100 million to advance an experimental treatment for mood disorders. In an OHSU News story, co-founder Tom Scanlan, Ph.D., says, “This is huge. I’ve always believed these drugs would be useful in the clinic. I’ve always believed that very strongly. It’s exciting to see us getting closer and closer.”

Maria Fleseriu, M.D., discusses clinical trials testing osilodrostat for the treatment of Cushing’s disease, in a video interview.